NasdaqGS:RGNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has REGENXBIO's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RGNX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.0%

RGNX

-3.0%

US Biotechs

-1.3%

US Market


1 Year Return

-29.7%

RGNX

33.9%

US Biotechs

18.5%

US Market

Return vs Industry: RGNX underperformed the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: RGNX underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

RGNXIndustryMarket
7 Day-6.0%-3.0%-1.3%
30 Day-9.9%1.8%5.3%
90 Day-29.0%-3.7%7.5%
1 Year-29.7%-29.7%36.2%33.9%21.3%18.5%
3 Year-11.5%-11.5%19.1%13.1%42.4%32.9%
5 Year83.9%83.9%15.2%7.0%84.2%63.5%

Price Volatility Vs. Market

How volatile is REGENXBIO's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is REGENXBIO undervalued compared to its fair value and its price relative to the market?

2.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RGNX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RGNX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RGNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: RGNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RGNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RGNX is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is REGENXBIO forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-13.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RGNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RGNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RGNX's revenue (16.5% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: RGNX's revenue (16.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RGNX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has REGENXBIO performed over the past 5 years?

-9.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RGNX is currently unprofitable.

Growing Profit Margin: RGNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RGNX is unprofitable, and losses have increased over the past 5 years at a rate of 9.6% per year.

Accelerating Growth: Unable to compare RGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: RGNX has a negative Return on Equity (-33.89%), as it is currently unprofitable.


Next Steps

Financial Health

How is REGENXBIO's financial position?


Financial Position Analysis

Short Term Liabilities: RGNX's short term assets ($329.1M) exceed its short term liabilities ($40.2M).

Long Term Liabilities: RGNX's short term assets ($329.1M) exceed its long term liabilities ($11.7M).


Debt to Equity History and Analysis

Debt Level: RGNX is debt free.

Reducing Debt: RGNX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RGNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RGNX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 18.8% each year


Next Steps

Dividend

What is REGENXBIO current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Ken Mills (45 yo)

11.58yrs

Tenure

US$6,147,269

Compensation

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills served as the Chief Financial Officer and Vice President of Busines ...


CEO Compensation Analysis

Compensation vs Market: Ken's total compensation ($USD6.15M) is above average for companies of similar size in the US market ($USD2.85M).

Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Kenneth Mills
CEO, President & Director11.58yrsUS$6.15m0.65%
$ 6.5m
Vittal Vasista
Chief Financial Officer11.17yrsUS$2.18m0.52%
$ 5.3m
Patrick Christmas
Chief Legal Officer4.17yrsUS$1.83m0.0069%
$ 69.4k
Olivier Danos
Chief Scientific Officer3.58yrsUS$1.93m0.018%
$ 183.6k
Stephen Pakola
Chief Medical Officer1.5yrsUS$4.01m0%
$ 0
Curran Simpson
Chief Operations & Technology Officerno dataUS$1.90m0.011%
$ 106.5k
Andrew Yost
Vice President of Corporate Development3.58yrsno datano data
Shiva Fritsch
Chief People Officer3yrsno datano data
Laura Coruzzi
Senior Vice President of Intellectual Property4.42yrsno datano data
Ram Palanki
Senior VP of Commercial Strategy & Operations2.17yrsno datano data
Sara Berl
Vice President of Law and Policy4.17yrsno datano data
Stephen Yoo
Consultant1.83yrsUS$1.88m0%
$ 0

3.6yrs

Average Tenure

51yo

Average Age

Experienced Management: RGNX's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kenneth Mills
CEO, President & Director11.58yrsUS$6.15m0.65%
$ 6.5m
David Stump
Independent Director5yrsUS$323.32k0%
$ 0
Daniel Abdun-Nabi
Independent Director4.17yrsUS$318.32k0%
$ 0
Argeris Karabelas
Lead Independent Director0.25yrUS$317.82k0%
$ 0
Inder Verma
Member of Scientific Advisorno datano datano data
Luke Beshar
Independent Director5.5yrsUS$333.32k0%
$ 0
Allan Fox
Chairman of the Board0.25yrUS$309.32k8.15%
$ 82.1m
Judith Swain
Member of Scientific Advisorno datano datano data
Alexandra Glucksmann
Independent Director2.42yrsUS$312.83k0%
$ 0
Daniel Tassé
Independent Director4.17yrsUS$315.32k0%
$ 0

4.2yrs

Average Tenure

66.5yo

Average Age

Experienced Board: RGNX's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

REGENXBIO Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: REGENXBIO Inc.
  • Ticker: RGNX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.008b
  • Shares outstanding: 37.33m
  • Website: https://www.regenxbio.com

Number of Employees


Location

  • REGENXBIO Inc.
  • 9600 Blackwell Road
  • Suite 210
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RGNXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDSep 2015
RB0DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2015

Biography

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 23:41
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.